Shahab Siddiqui, MD
Sports Medicine · Hagerstown, MDNPI 1962448902
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 213 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 27 manufacturers reported payments, led by AstraZeneca at 29.9% of the total.
Across 213 payments — averaging $19.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$664
- GSK$492
- Lilly USA, LLC$420
- Pfizer$170
- Johnson & Johnson$125
- plus $983 from 21 others
What the payments were for
- Food & beverage$4,073100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 64 | $1,218 |
| Novo Nordisk | 33 | $664 |
| GSK | 22 | $492 |
| Lilly USA, LLC | 23 | $420 |
| Pfizer | 9 | $170 |
| Johnson & Johnson | 7 | $125 |
| Bayer | 7 | $124 |
| AbbVie | 6 | $114 |
| Amarin Pharma, Inc. | 5 | $80 |
| E.r. Squibb & Sons, L.L.C. | 4 | $68 |
| Novartis | 4 | $67 |
| Exact Sciences | 3 | $64 |
| Boehringer Ingelheim | 3 | $58 |
| Amgen | 2 | $53 |
| Phathom Pharmaceuticals, Inc. | 2 | $48 |
| Sanofi-aventis U.S. LLC | 3 | $47 |
| Sunovion Pharmaceuticals Inc. | 2 | $37 |
| Astellas Pharma US Inc | 2 | $37 |
| Nestle Healthcare Nutrition Inc. | 2 | $36 |
| Kowa Pharmaceuticals America, Inc. | 2 | $31 |
| Otsuka America Pharmaceutical, Inc. | 2 | $25 |
| Smith+Nephew | 1 | $18 |
| Medtronic | 1 | $17 |
| Mallinckrodt Hospital Products Inc. | 1 | $16 |
| Xeris Pharmaceuticals, Inc. | 1 | $16 |
| Strongbridge US Inc. | 1 | $14 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Ozempic$100
How this compares
$4,073 in reported general payments places this provider in the 65th percentile of 111 sports medicine providers in Maryland.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TrulicityDulaglutide | 134 | $178,535 |
| EliquisApixaban | 133 | $163,587 |
| OzempicSemaglutide | 84 | $93,622 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 84 | $80,495 |
| RybelsusSemaglutide | 34 | $70,370 |
| MounjaroTirzepatide | 38 | $60,527 |
| JardianceEmpagliflozin | 37 | $46,845 |
| FarxigaDapagliflozin Propanediol | 33 | $44,765 |
| XareltoRivaroxaban | 23 | $35,016 |
| JanuviaSitagliptin Phosphate | 18 | $23,036 |
| EntrestoSacubitril/Valsartan | 17 | $19,450 |
| Tresiba Flextouch U-100Insulin Degludec | 28 | $19,198 |
| Tresiba Flextouch U-200Insulin Degludec | 28 | $16,809 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 37 | $16,653 |
| LinzessLinaclotide | 14 | $11,377 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCTrulicity, Mounjaro | $420 | $239,062172 claims |
| Novo NordiskOzempic, Rybelsus | $664 | $163,992118 claims |
| PfizerEliquis | $170 | $163,587133 claims |
| GSKTrelegy Ellipta | $492 | $80,49584 claims |
| Boehringer IngelheimJardiance | $58 | $46,84537 claims |
| AstraZenecaFarxiga | $1,218 | $44,76533 claims |
| Johnson & JohnsonXarelto | $125 | $35,01623 claims |
| NovartisEntresto | $67 | $19,45017 claims |
| AbbVieLinzess | $114 | $11,37714 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 111 sports medicine providers in Maryland.
Other sports medicine in Hagerstown
- Paul MyersHagerstown$34K
- Scott WorrellHagerstown$2K
- Garrett LynchAnnapolis$1.4M
- Raymond ThalBethesda$779K
- Jason ScoppSalisbury$637K
- John ChristoforettiBethesda$418K
- Jonas RudzkiChevy Chase$386K
- Matthew LevineFrederick$364K
- Abdulaziz AhmedBaltimore$85K
- Taylor WileySalisbury$53K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.